Memphasys inks landmark Middle East deal for Felix system

Memphasys has taken a decisive step on its commercial journey with a binding five year distribution agreement that brings its flagship Felix sperm preparation system into the heart of the Middle East and North Africa.

The agreement with Doha based International Technical Legacy (ITL) grants exclusivity across 15 countries covering more than 350 IVF clinics. It is immediately underpinned by a minimum order worth 325 thousand dollars, triggered once the Felix device receives its long awaited CE Mark approval.

The Felix system separates the most viable sperm cells using a patented bio separation process. While it has long been a promising piece of reproductive biotechnology, Memphasys has needed a pathway into the highly fragmented and competitive global IVF market. With ITL on board, the company gains access to a region where around 140,000 IVF cycles are performed annually.

ITL will not only handle distribution but will also provide training, market access and after sales support. Importantly, the group has first refusal rights over future Memphasys reproductive technologies, tying the two companies together well beyond this deal.

Memphasys chief executive Dr David Ali described the agreement as a major milestone. “ITL is the clear leader in IVF infrastructure and consumables in the Middle East, and their established relationships with more than 350 clinics provides an immediate pathway to market. The initial binding order upon CE Mark approval provides near term revenue certainty, while the scale of the opportunity and ITL’s clinical expertise underpin the potential for long term recurring revenues,” he said.

ITL chairman Madame Raffia Fekri was equally upbeat. “We chose Felix as it is a new innovative and fast technology that shows the potential to displace other techniques in the market. This agreement allows us to introduce this innovative, proven technology that will benefit families and clinicians across the region,” she said.

The commercial framework is designed to embed Felix quickly. Consoles will be supplied free of charge to new clinics, ensuring cost is not a barrier to adoption. Revenues will be driven by sales of single use cartridges, providing Memphasys with the recurring cash flow typical of razor and blade models.

Memphasys expects CE Mark approval within 12 months, with immediate deliveries to follow. The company is also pursuing similar arrangements in Japan, India and New Zealand, where negotiations are in advanced stages. These, together with direct sales efforts in selected territories, are expected to generate meaningful revenue in financial year 2026.

For Memphasys, which has spent years developing Felix, the deal represents more than just a regional partnership. It is the first tangible sign that the company’s pivot to commercialisation is gaining traction. If ITL can seed the Middle East with Felix as expected, the model could be replicated in other key IVF markets, giving the Australian company a global footprint in assisted reproduction technology.